Richard Dale Huhn

Richard Dale Huhn

Auto-generated profile, based on publicly available information

Richard Dale Huhn

Biothera Pharmaceuticals, Inc., Eagan, MN 55121; and

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2014 in Leukemia Research
Verified
Journal Article
Closed access
JWJennifer A. Westwood
Jennifer A. Westwood
GMGeoffrey M. Matthews
Geoffrey M. Matthews
JSJake Shortt
Jake Shortt
DFDavid Faulkner
David Faulkner
HPHollie J. Pegram
Hollie J. Pegram
Michael KershawMichael Kershaw
Michael Kershaw

15 May 2019 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
NBNandita Bose
Nandita Bose
NONadine R. Ottoson
Nadine R. Ottoson
XQXiaohong Qiu
Xiaohong Qiu
BHBen Harrison
Ben Harrison
JLJamie R. Lowe
Jamie R. Lowe
RHRichard D. Huhn
Richard D. Huhn
Imprime PGG (Imprime) is an i.v. administered, yeast β-1,3/1,6 glucan in clinical development with checkpoint inhibitors. Imprime-mediated innate immune activation requires immune complex formation with naturally occurring IgG anti-β glucan Abs (ABA). We administered Imprime to healthy human volunteers to assess the necessity of ABA for Imprime-mediated immunopharmacodynamic (IPD) changes. Imprime (4 mg/kg) was administered i.v. in single and multiple infusions. Subsets of subjects were premedicated with antihistamine and corticosteroid. Peripheral blood was measured before, during and after Imprime administration for IPD changes (e.g., ABA, circulating immune complexes, complement activation, complete blood counts, cytokine/chemokine, and gene expression changes). IPD changes were analyzed based on pretreatment serum ABA levels: low-ABA (<20 μg/ml), mid-ABA (≥20–50 μg/ml), and high-ABA (≥50 μg/ml). At the end of infusion, free serum ABA levels decreased, circulating immune complex levels increased, and complement activation was observed. At ∼1–4 h after end of infusion, increased expression of cytokines/chemokines, a 1.5-4-fold increase in neutrophil and monocyte counts and a broad activation of innate immune genes were observed. Low-ABA subjects typically showed minimal IPD changes except when ABA levels rose above 20 μg/ml after repeated Imprime dosing. Mild-to-moderate infusion-related reactions occurred in subjects with ABA ≥20 μg/ml. Premedications alleviated some of the infusion-related reactions, but also inhibited cytokine responses. In conclusion, ABA levels, being critical for Imprime-mediated immune activation may provide a plausible, mechanism-based biomarker to identify patients most likely to respond to Imprime-based anticancer immunotherapy.

20 May 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JIJose Luis Iglesias
Jose Luis Iglesias
RPRadha Prathikanti
Radha Prathikanti
Bo MaBo Ma
Bo Ma
PMPaulette Mattson
Paulette Mattson
DKDeb Kedrowski
Deb Kedrowski
MCMichael Jon Chisamore
Michael Jon Chisamore
TPS3105 Background: Imprime PGG (Imprime) is a Pathogen-Associated Molecular Pattern that enhances innate immune cell killing, counteracts immune suppression and triggers activation and maturation of antigen presenting cells. Imprime’s ability to trigger a coordinated innate and adaptive immune response is critical for enhancing the efficacy of CPIs in several pre-clinical tumor models. We are now exploring the combination of PGG beta-glucan and Pembrolizumab, a humanized mAb against programmed death receptor-1 (PD-1) in the clinic. In previous trials, Pembro yielded a 33% ORR and 23 mo mOS in 655 pts with advanced MEL and an 18.5% ORR and 11.2 mo mOS in 27 evaluable pts with metastatic/recurrent TNBC (Ribas et al., 2016; Nanda et al., 2016). Pre-treatment levels of anti-beta glucan antibodies (ABA) are correlated with pt response to Imprime. Methods: This Phase 2 study is enrolling ABA positive pts with advanced MEL following progression on treatment with a CPI or metastatic TNBC failing front-line chemotherapy. The study is a Simon optimal 2-stage design with sample size of 12 pts of each tumor type in Stage 1. If response and AE criteria (≤ 4 [or ≤ 33%] pts with grade 3/4 in Cycle 1) for each tumor type are met, an additional 17 pts with MEL and 30 pts with TNBC will be enrolled in Stage 2. Primary endpoints of the study are ORR (based on RECIST 1.1) and safety. Secondary endpoints include TTR, CRR, DoR, PFS, and OS. PK data will be profiled. Exploratory endpoints include ORR and PFS based on irRECIST, analysis of an ABA biomarker, immune cell activation markers, and changes in the tumor immune microenvironment. Screening and enrollment are underway in the US. Biothera Pharmaceuticals, Inc. is sponsoring the trial (ClinicalTrials.gov NCT02981303) under a collaborative agreement with Merck. Clinical trial information: NCT02981303.

16 March 2015 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
ABA. Braun
A. Braun
WEW. Engel-Riedel
W. Engel-Riedel
FSF. Schneller
F. Schneller
MWM. Wolf
M. Wolf
WSW. Schuette
W. Schuette
RHR. Huhn
R. Huhn
Aim: Imprime PGG (PGG) in combination with carboplatin/paclitaxel chemotherapy (C/P) and an EGFR-targeted antibody (cetuximab; Cet) increased objective response rates (ORR) compared to C/P + Cet alone (Schneller et al, J Thorac Oncol 2014; Vol 9 [Suppl 14], S40). This identically designed phase 2 trial evaluated PGG in combination with C/P and Bev in patients (pts) with stage IV non-squamous (no-sq) NSCLC.

20 January 2015 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
RHRichard Dale Huhn
Richard Dale Huhn
JLJamie Lowe
Jamie Lowe
MGMichele Grady
Michele Grady
CTCorina Candiani Taitt
Corina Candiani Taitt
MGMichele Anne Gargano
Michele Anne Gargano
ABAda H. Braun
Ada H. Braun
TPS787 Background: Imprime PGG (Imprime) is a novel immune modulator (complex carbohydrate biologic), which harnesses innate immune cells to enhance killing of antibody-targeted tumor cells. In a phase 2 single-arm clinical trial in mCRC, the combination of Imprime with cetuximab resulted in 24% ORR, 62% disease control rate (DCR), and median time to progression (TTP) of 12 wks (Tamayo ME, Ann Onc 2010), representing approximate 100% increases vs historical control (Cunningham, NEJM 2004). ORR was 45%, DCR, 82% and TTP, 24 wks in pts with KRAS WT tumors (post hoc analysis). Single-agent cetuximab has been shown to improve objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) in patients (pts) with epidermal growth factor receptor (EGFR) expressing, KRAS wild-type (WT) metastatic colorectal cancer (mCRC) who failed oxaliplatin- and irinotecan-based therapy or are intolerant to irinotecan. The mechanism of action of cetuximab is thought to rely on competitive blockade of endogenous ligand binding and downstream signaling, internalization and down regulation of EGFR, as well as antibody-dependent cellular cytotoxicity (ADCC) (Erbitux SmPC). The current trial, sponsored by Biothera (registered with ClinicalTrials.gov NCT01309126) is to confirm these findings in phase 3. Methods: Eligible pts will have had prior oxaliplatin- and irinotecan-based therapy or be intolerant to irinotecan, and will meet key inclusion criteria including measurable disease and ECOG performance status of 0 or 1. In a 2:1 randomization, stratified by geographic region, prior chemotherapy and site, approximately 795 pts will receive weekly open-label Imprime plus cetuximab or cetuximab alone. The primary endpoint of the study is OS and primary analysis will occur when ~709 deaths have occurred. Secondary endpoints include PFS, ORR (based on RECIST 1.1), quality of life, safety and pharmacokinetics. Exploratory endpoints include biomarker analyses. Pt screening and enrollment is underway in the United States and Europe. Clinical trial information: NCT01309126.